Share

CLINICAL TRIAL SEARCH RESULTS

NEW SEARCH
 Number: 201304108 Principal Investigator: Chapman, William
Title: A Phase II Randomized Multicenter Placebo-Controlled Blinded Study of Sorafenib Adjuvant Therapy in High Risk Orthotopic Liver Transplant (OLT) Recipients with Hepatocellular Carcinoma (HCC)
Description: This is a research study for patients who received a liver transplant and are at high risk of liver cancer recurrence after liver transplant. It is not known whether sorafenib, the study medication, is effective in preventing cancer recurrence in high risk patients following liver transplantation. T...MORE
___________________________________________________________________________________________________
 Number: RTOG 1112 Principal Investigator: Olsen, Jeffrey
Title: Randomized Phase III Study of Sorafenib versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma
Description: The standard treatment for hepatocellular carcinoma that is unsuitable for surgery or regional therapy is sorafenib, an oral drug that has been shown to increase the survival of patients compared to no active treatment. Stereotactic body radiation therapy (SBRT), referring to the use of focused hig...MORE
___________________________________________________________________________________________________
 Number: CALGB 80802 Principal Investigator: Tan, Benjamin
Title: Phase III randomized study of Sorafenib plus Doxorubicin versus Sorafenib in patients with Advanced Hepatocellular Carcinoma (HCC)
Description: The purpose of this study is to compare the effects (good and bad) of the drug sorafenib with the combination of sorafenib plus doxorubicin on patients and their advanced primary liver cancer to find out which is better....MORE
___________________________________________________________________________________________________
 Number: 201310140 Principal Investigator: Amin, Manik
Title: Phase 2 Study of SPI-1620 in Combination with Docetaxel as a Second-Line Treatment for Patients with Advanced Biliary Cancer
Description: The purpose of this study is to determine whether adding an investigational drug, SPI-1620, to standard treatment with docetaxel will help treat biliary cancer....MORE
___________________________________________________________________________________________________
 Number: 201307059 Principal Investigator: Tan, Benjamin
Title: A Multicenter, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma
Description: The main purpose of this study is to find out whether patients with hepatocellular carcinoma who receive lenvatinib live longer compared to patients who receive sorafenib....MORE
___________________________________________________________________________________________________
 Number: 201306051 Principal Investigator: Tan, Benjamin
Title: A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects with Hepatocellular Carcinoma Who Have Received Prior Sorafenib
Description: The purpose of this study is to find out if cabozantinib is effective in treating liver cancer. This study will also examine how safe cabozantinib is and how well people with liver cancer tolerate cabozantinib....MORE
___________________________________________________________________________________________________
 Number: 201301150 Principal Investigator: Tan, Benjamin
Title: A randomized, double blind, placebo-controlled, multicenter phase III study of regorafenib in patients with hepatocellular carcinoma (HCC) after sorafenib
Description: The purpose of this study is to assess if regorafenib in combination with best supportive care is safe and will slow down the growth of tumor or even shrink the tumor and result in increased survival in patients who experienced failure of previous sorafenib treatment....MORE
___________________________________________________________________________________________________
 Number: 201202001 Principal Investigator: Zuckerman, Darryl
Title: A Phase III Clinical Trial Evaluating TheraSphere in Patients with Metastatic Colorectal Carcinoma of the Liver who have Failed First Line Chemotherapy
Description: The purpose of this research study is to examine whether adding treatment with TheraSphere early in the current standard for second-line chemotherapy treatment of metastatic colorectal cancer is better than the current treatment alone. Better means slowing or stopping the growth of liver tumors ...MORE
___________________________________________________________________________________________________
 Number: ACRIN 6690 Principal Investigator: Fowler, Kathryn
Title: A Prospective, Multicenter Comparison of Multiphase Contrast-Enhanced CT and Multiphase Contrast-Enhanced MRI for Diagnosis of Hepatocellular Carcinoma and Liver Transplant Allocation
___________________________________________________________________________________________________
 Number: 201106049 Principal Investigator: Chapman, William
Title: The Hepatic Research Registry
___________________________________________________________________________________________________
 Number: 201301098 Principal Investigator: Owen, Joseph
Title: A Revisit of Complete Radiologic Response of Colorectal Liver Metastases (Disappearing Lesions) in the Era of Eovist (Gadoxetate Disodium)
___________________________________________________________________________________________________
 Number: P2C MC0845 Principal Investigator: Picus, Joel
Title: A Phase II Trial of Temsirolimus and Bevacizumab in Patients with Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid, or Islet Cell Cancer
Description: This study is being done to learn what effects (good and bad) the combination of temsirolimus and bevacizumab has on you and your cancer. The combination of these two drugs is currently being tested in patients with kidney cancer through another study. Although preliminary results from this study ar...MORE
___________________________________________________________________________________________________